Abcellera Biologics Inc ABCL

$11.88 +0.75 (6.74%)

Valuation

Market cap: 3,412,580,000
Revenue TTM: $75,130,000
Net income TTM: $-146,410,000
P/E (trailing): 0.00
P/E (forward): —
Profit margin: -194.88%
Debt to equity: 0.00

Trading

Volume: 2,208,400
Avg volume: 4,428,534
Day's range: $11.20 – $11.98
Shares out: 306,611,000
Stochastic %K: 36%
Beta: 1.59
Analysts: Strong Buy
Price target: $17.17

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Website: https://www.abcellera.com
Address: 150 W 4th Avenue, Vancouver, Canada

Latest news

No headlines yet.

Stocktwits

Stocktradesmoon Nov 7, 6:45 AM

$ABCL $HIMS $SLS $SYRE $REGN "The only way to get your break is to keep showing up, keep grinding and keep finding a way to make it to another practice until luck finds you." - Danny Amendola, undrafted super bowl champion

0 replies

GTA_Terminal Nov 7, 3:44 AM

Dark pool check on $ABCL: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=ABCL&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=ABCL Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-abcellera-biologics-abcl-2?utm_source=stocktwits&utm_medium=social

0 replies

SuperGreenToday Nov 7, 1:02 AM

$ABCL Share Price: $11.89 Contract Selected: Apr 16, 2027 $10 Calls Buy Zone: $2.80 – $3.46 Target Zone: $5.05 – $6.17 Potential Upside: 70% ROI Time to Expiration: 159 Days | Updates via https://fxcapta.com/stockinfo/

0 replies

ElongTSLA Nov 6, 11:41 PM

$ABCL There are a lot of interesting catalysts for November specifically. I'm particularly interested in the earnings call, and also the November 16 and November 17 Institutional Investor Engagements. @Stocktradesmoon thanks for putting this on my radar. I think there is a lot of upside on ABCL.

1 replies

Stocktradesmoon Nov 6, 8:36 PM

$ABCL Phenotype of a company that has the potential to scale up and be the next $REGN $VRTX $LLY $PFE 1. Needs a blockbuster that it wholly owns 2. Capabilities internally to reproducibly develop drugs 3. Pipeline to show its worth more than a single asset - Carl Hansen

0 replies

Stocktradesmoon Nov 6, 8:08 PM

$ABCL ❤️ $REGN $PFE $SLS $MRNA WHO’S EXCITED 😆 for NEXT WEEK?!!!! 😊 ABcellera 🔥!!! 👀🚀 👀🚨 4 MAJOR Catalyst Events All HAPPENING in a few days!! 👀👏🚀 — November could be more important than the recent share price rally. Here’s exactly what I’m watching. November 9: Q3 earnings and pipeline update. November 11: Stifel Healthcare Conference. November 16: Jefferies Global Healthcare Conference in London. AND… We got MORE NEWS 🗞️ YESTERDAY After-Hours!! + ABcellera to Present @ the UBS GLOBAL BIOPHARMA Conference on November 17, 2026!!

0 replies

Stocktradesmoon Nov 6, 8:02 PM

$ABCL ❤️ $MRNA $SLS $LLY $REGN ABcellera 🔥 🔥 UPGRADES!!! BOOM!! Price targets (👀New Upgrade JEFFERIES $21🎯 🔵 Truist Securities — $30 🔴 JonesTrading — $25 🟡 UBS — $18 🟢 JPMorgan — $17 🟣 BMO Capital — $15 🟠 Goldman Sachs — $13 🩵 Cantor Fitzgerald — $12 🩷 Stifel — $9 ABCL — ANALYST PRICE TARGETS (USD) Truist Securities: $12 → $30 (+150%) JonesTrading: $13 → $25 (+92.3%) UBS: $18 (New Coverage) JPMorgan: $17 (New Coverage) BMO Capital: $15 Goldman Sachs: $13 (New Coverage) Cantor Fitzgerald: $11 → $12 (+9.1%) Stifel: $8 → $9 (+12.5%) 👀🚨🔥JonesTrading analyst Debanjana Chatterjee reiterated a Buy rating on AbCellera Biologics and set a price target of $25.00. She’s actually a very accurate Analyst!! So this is a STRONG SIGNAL $25’ssss!

0 replies

Stocktradesmoon Nov 6, 6:57 PM

$ABCL $REGN $PFE $SLS $MRNA

1 replies